Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Lemieux Pierre

2. Date of Event Requiring Statement (MM/DD/YYYY) 4/1/2020

3. Issuer Name and Ticker or Trading Symbol

Acasti Pharma Inc. [ACST]

(Last) (First) (Middle)

C/O ACASTI PHARMA INC., 545 PROMENADE DU CENTROPOLIS, SUITE 100

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
COO & CSO /

(Street)

LAVAL, A8 H7T 0A3

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	7000	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share Option (Right to Buy)	⁽¹⁾	6/1/2022	Common Shares	16900	$4.50 ⁽¹⁰⁾	D
Share Option (Right to Buy)	⁽²⁾	5/30/2023	Common Shares	31400	$1.99 ⁽¹⁰⁾	D
Share Option (Right to Buy)	⁽³⁾	2/24/2027	Common Shares	50000	$1.65 ⁽¹⁰⁾	D
Share Option (Right to Buy)	⁽⁴⁾	6/14/2027	Common Shares	93000	$1.77 ⁽¹⁰⁾	D
Share Option (Right to Buy)	⁽⁵⁾	6/14/2027	Common Shares	62000	$1.77 ⁽¹⁰⁾	D
Share Option (Right to Buy)	⁽⁶⁾	7/2/2028	Common Shares	365515	$0.77 ⁽¹⁰⁾	D
Share Option (Right to Buy)	⁽⁷⁾	4/15/2029	Common Shares	79300	$1.28 ⁽¹⁰⁾	D
Share Option (Right to Buy)	⁽⁸⁾	4/15/2029	Common Shares	270700	$1.28 ⁽¹⁰⁾	D
Share Option (Right to Buy)	⁽⁹⁾	3/31/2030	Common Shares	587000	$0.53 ⁽¹⁰⁾	D

Explanation of Responses:
(1)	Represents 16,900 common shares underlying 16,900 share options granted on June 1, 2015. These share options vested in 12 equal installments on a quarterly basis starting from June 1, 2015 until June 1, 2018.
(2)	Represents 31,400 common shares underlying 31,400 share options granted on May 30, 2016. These share options vested in 12 equal installments on a quarterly basis starting from May 30, 2016 until May 30, 2019.
(3)	Represents 50,000 common shares underlying 50,000 share options granted on February 24, 2017. These share options vested in 12 equal installments on a quarterly basis starting from February 24, 2017 until February 24, 2020.
(4)	Represents 93,000 common shares underlying 93,000 share options granted on June 14, 2017. These share options vest in 12 equal installments on a quarterly basis starting from June 14, 2017 until June 14, 2020.
(5)	Represents 62,000 common shares underlying 62,000 share options granted on June 14, 2017. These share options vest in 12 equal installments on a quarterly basis starting from June 14, 2017 until June 14, 2020.
(6)	Represents 365,515 common shares underlying 365,515 share options granted on July 2, 2018. These share options vest in 12 equal installments on a quarterly basis starting from July 2, 2018 until July 2, 2021.
(7)	Represents 79,300 common shares underlying 79,300 share options granted on April 15, 2019. These share options vest in 12 equal installments on a quarterly basis starting from April 15, 2019 until April 15, 2022.
(8)	Represents 270,700 common shares underlying 270,700 share options granted on April 15, 2019. These share options vest in 12 equal installments on a quarterly basis starting from April 15, 2019 until April 15, 2022.
(9)	Represents 587,000 common shares underlying 587,000 share options granted on March 31, 2020. These share options vest in 12 equal installments on a quarterly basis starting from March 31, 2020 until March 31, 2023.
(10)	Canadian dollars.

Remarks:
Exhibit List - Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Lemieux Pierre C/O ACASTI PHARMA INC. 545 PROMENADE DU CENTROPOLIS, SUITE 100 LAVAL, A8 H7T 0A3			COO & CSO